Legend Biotech
LB2501 is a CD19/CD20 in vivo CAR-T candidate using the TaVec lentiviral platform, with an ongoing China Phase 1 study (NCT07002112). Its October 2026 U.S. IND clearance supports a planned Phase 1/2 study. Neither IND clearance nor early responses constitute approval.
Corporate information
- Company entity
- Legend Biotech
- Headquarters / principal office
- Bridgewater, New Jersey, USACorporate website explicitly identifies headquarters; location follows the retrieved disclosure. ↗
- Founded
- 2014 ↗
- Ownership / capital status
- Publicly tradedPublicly traded (Nasdaq: LEGN); public-market transactions tracked separately ↗
- Official corporate reference
- https://legendbiotech.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
LB2501 is a CD19/CD20 in vivo CAR-T candidate using the TaVec lentiviral platform, with an ongoing China Phase 1 study (NCT07002112). Its October 2026 U.S. IND clearance supports a planned Phase 1/2 study. Neither IND clearance nor early responses constitute approval.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Legend Biotech — primary program / ownership disclosure
- Legend Biotech — supporting primary disclosure
- Legend global headquarters
- Legend official corporate history